info@synchemia.com | sales@synchemia.com 
9766925136 
Enasidenib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.Enasidenib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Enasidenib Nitroso Impurity 2 CAS NO: NA chemically represented as N-(4-((2-Hydroxy-2-methylpropyl)(nitroso)amino)-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)nitrous amide. Synchemia is the leading manufacturing and exporter of Enasidenib Nitroso Impurity 2 . We supply Enasidenib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Related Products
| CAT No | SRC-N0142515 |
| CAS No | NA |
| Mol.F. | C15H20N2O5 |
| Mol.Wt. | 308.3 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142516 |
| CAS No | NA |
| Mol.F. | C18H23N3O6 |
| Mol.Wt. | 377.4 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142517 |
| CAS No | NA |
| Mol.F. | C26H31N3O6 |
| Mol.Wt. | 481.5 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142518 |
| CAS No | NA |
| Mol.F. | C22H31N3O6 |
| Mol.Wt. | 433.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142519 |
| CAS No | NA |
| Mol.F. | C15H26N2O5 |
| Mol.Wt. | 314.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142520 |
| CAS No | NA |
| Mol.F. | C3H3N3O |
| Mol.Wt. | 97.08 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142521 |
| CAS No | NA |
| Mol.F. | C24H25F2N9O |
| Mol.Wt. | 493.5 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142522 |
| CAS No | NA |
| Mol.F. | C24H24F2N10O2 |
| Mol.Wt. | 522.5 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142523 |
| CAS No | NA |
| Mol.F. | C8H7BFN3O3 |
| Mol.Wt. | 223.0 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142524 |
| CAS No | NA |
| Mol.F. | C10H14N4O |
| Mol.Wt. | 206.2 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142525 |
| CAS No | NA |
| Mol.F. | C27H31F2N9O2 |
| Mol.Wt. | 551.60 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142526 |
| CAS No | NA |
| Mol.F. | C27H31F2N9O2 |
| Mol.Wt. | 551.60 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142527 |
| CAS No | NA |
| Mol.F. | C27H32FN9O |
| Mol.Wt. | 517.61 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142528 |
| CAS No | NA |
| Mol.F. | C27H31F2N9O2 |
| Mol.Wt. | 551.60 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142529 |
| CAS No | NA |
| Mol.F. | C27H31F2N9O3 |
| Mol.Wt. | 567.60 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142530 |
| CAS No | NA |
| Mol.F. | C28H32N4O4 |
| Mol.Wt. | 488.6 g/mol |
| INV STATUS | In Stock |
